VALN Earnings Date: Nov 19, 2026 (Estimated) — Valneva SE
NASDAQ · Healthcare · Biotechnology
Updated
When is VALN's next earnings date?
Valneva SE (VALN) is expected to report Q3 2026 earnings on Thursday, November 19, 2026 at 1:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.23 on revenue of $43.7M.
How did VALN do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), Valneva SE posted EPS of -$0.40 versus the -$0.28 estimate, a miss of 41.1%. Revenue was $40.6M against a $48.2M estimate. The stock's 1-day post-earnings move was +1.8%.
How much does VALN stock move after earnings?
VALN beat EPS estimates in 2 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.4% (up or down) in the day after earnings.
About Valneva SE
Valneva SE operates as a specialized biopharmaceutical company, concentrating its efforts on developing and bringing to market preventative vaccines for infectious diseases where current medical options are insufficient. Its portfolio of commercial travel vaccines includes IXIARO, an inactivated vaccine derived from Vero cell culture, which provides active immunity against Japanese encephalitis. Another offering is DUKORAL, an oral vaccine designed to guard against diarrhea induced by Vibrio cholerae or enterotoxigenic Escherichia coli (ETEC) bacteria. The company's development pipeline features VLA2001, a candidate vaccine targeting SARS-CoV-2. Additionally, Valneva is progressing with VLA15, a Lyme disease vaccine candidate that has successfully concluded Phase II clinical trials and is being co-developed and commercialized with Pfizer, Inc. They are also advancing VLA1553, a chikungunya virus vaccine candidate currently undergoing Phase III clinical evaluation, in partnership with Instituto Butantan for its development, production, and marketing as a single-shot vaccine. Valneva's products are sold across a wide geographical area, including the United States, Canada, Germany, Austria, the Nordic countries, the United Kingdom, various other European nations, and internationally. Founded in 1998, the company maintains its headquarters in Saint-Herblain, France.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.28 | -0.40 | -41.07% | $40.6M | ❌ Miss | +1.80% | +23.24% | +20.00% |
| 2026-05-13 | Q1 2026 | -0.21 | -0.42 | -100.48% | $36.2M | ❌ Miss | -2.17% | -4.00% | -11.83% |
| 2026-03-18 | Q4 2025 | -0.21 | -0.68 | -221.43% | $55.5M | ❌ Miss | +1.63% | -41.69% | -45.78% |
| 2025-11-20 | Q3 2025 | -0.30 | -0.61 | -103.33% | $34.4M | ❌ Miss | -1.95% | +9.66% | -7.18% |
| 2025-08-12 | Q2 2025 | -0.27 | -0.16 | +40.74% | $54.8M | ✅ Beat | +10.59% | +42.82% | +6.59% |
| 2025-03-20 | Q4 2024 | -0.22 | -0.54 | -145.45% | $56.5M | ❌ Miss | +7.73% | +6.39% | +0.89% |
| 2024-11-07 | Q3 2024 | -0.29 | -0.15 | +48.28% | $50.4M | ✅ Beat | -1.97% | -11.27% | -25.94% |
| 2024-08-13 | Q2 2024 | -0.30 | -0.37 | -23.33% | $41.0M | ❌ Miss | +7.35% | +23.34% | +0.86% |
Showing last 8 quarters.
Revenue by segment & region
By segment
FY2025 · $149.6M total · annual
| Segment | Share | Revenue | YoY | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| IXIARO | 65.8% | $98.4M | +4.6% | $41.4M | $73.5M | $94.1M | $98.4M |
| DUKORAL | 21.3% | $31.9M | -1.2% | $17.3M | $29.8M | $32.3M | $31.9M |
| Third Party Products | 12.8% | $19.2M | -42.3% | $26.5M | $35.7M | $33.2M | $19.2M |
| Other Services | 0.1% | $87K | -92.3% | — | — | $1.1M | $87K |
By region
FY2025 · $162.0M total · annual
| Segment | Share | Revenue | YoY | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| UNITED STATES | 33.1% | $53.6M | +10.3% | $33.0M | $48.6M | $53.6M |
| CANADA | 18.6% | $30.1M | -6.8% | $28.2M | $32.3M | $30.1M |
| GERMANY | 10.8% | $17.5M | -4.9% | $13.5M | $18.4M | $17.5M |
| FRANCE | 9.1% | $14.7M | +103.2% | $5.9M | $7.2M | $14.7M |
| Nordics | 8.6% | $13.9M | -0.3% | $12.7M | $13.9M | $13.9M |
| Other Europe | 8.6% | $13.9M | +53.2% | $9.3M | $9.1M | $13.9M |
| AUSTRIA | 5.8% | $9.5M | -40.4% | $14.6M | $15.9M | $9.5M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.